NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)
NEW YORK, November 29, 2023--(BUSINESS WIRE)--NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to immediately suspend trading in the common stock of Timber Pharmaceuticals, Inc. (the "Company") — ticker symbol TMBR — from NYSE American.
On November 21, 2023, the NYSE American announced that it was commencing proceedings to delist the Company. The Company had the right to request a review of this determination by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. On November 28, 2023, the Company confirmed that it will not exercise that right. Accordingly, the NYSE American will now suspend trading in the common stock and will file a delisting application with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129559960/en/
Contacts
Company Contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chairman and Chief Executive Officer
jkoconis@timberpharma.com
NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com
